纳米科技对投药过程的影响

Summary:

This report examines the business opportunities that are being created by nano-engineered solutions for the drug delivery market. According to one source, approximately $65 billion in drug revenues every year are accounted for by pharmaceuticals with poor bio-availability which far too often results in higher patient costs and inefficient treatment but also, more importantly, increased risks of toxicity or even death. Because nanotechnology focuses on the very small it is uniquely suited to creating systems that can better deliver drugs to tiny areas within the body. Nano-enabled drug delivery also makes it possible for drugs to permeate through cell walls, which is of critical importance to the expected growth of genetic medicine over the next few years.

This NanoMarkets Report:

• Identifies and quantifies current and future market opportunities - This report examines the business prospects for new delivery materials and methods, tools, and end-use applications being enabled by developments in nanotechnology.
• Identifies key issues in the commercialization process - Chapter Three of this report covers several areas of concern in bringing nano-enabled drug delivery products to market. This includes information on the general business climate for startups and big pharma, fundraising strategies and caveats, how companies are shaping the intellectual property landscape, potential litigation issues, and possible exit scenarios for investors in related companies.
• Defines current and future applications for nanotechnology in drug delivery - It is widely perceived that the nanotechnology will have a profound effect on the pharmaceutical industry. Emerging nanotechnology tools and techniques are expected to reduce the required time and cost to bring a new drug delivery platform to-market. Nanotech-enabled drugs are beginning to fill the drug R&D pipeline, and perhaps extend the useful life of existing drugs. This report aims to highlight the major nano-enabled drug delivery technologies that are commercially available or under development.
• Analyzes the efforts of companies in nano-enabled drug delivery - Much of the difficulty in commercializing new technologies lies in execution. While most startups claim promising research with early human or animal clinical results, many will be unable to secure a profitable niche in the industry. NanoMarkets will comment on various collaborations, strategic alliances and/or partnerships with pharmaceutical companies, academic research institutions and biotechnology companies. We believe that such partnerships are vital for the success of nano-enabled drug delivery companies.
• Evaluates funding mechanisms for nanotechnology in the pharmaceutical environment - There are several sources of capital available for R&D, including traditional and corporate venture capital, debt financing, sponsored research and non-recurring engineering funds, federal & state grants, etc. Several government initiatives are in place that vary widely from region to region. This report addresses some of the regulatory issues and funding policies that are affecting the growth of nanotechnology and nano-enabled drug delivery on a global scale.
• Forecasts the market for new technologies broken out by drug delivery type and technology platform - Areas covered include encapsulation technologies, implantable delivery methods, imaging agents and microneedles. Technologies covered include dendrimers, nanotubes and fullerenes, nanoparticles, quantum dots and magnetic/electrical targeting methods.

This unique report will be of vital interest to drug delivery system manufacturers, other medical device manufacturers, pharmaceutical and biotech firms and healthcare providers. The report should also be of interest to financial industry professionals working in equity analysis, venture capital, investment banking and private equity firms.

Table of Contents

Executive Summary

Chapter One: Introduction

1.1 Background to Report

1.2 Objectives of this Report

1.3 Scope of Report

1.3.1 Research Methodology and Information Sources

1.4 Plan of Report

Chapter Two: Nanotechnology-Based Drug Delivery Technologies

2.1 Introduction

2.2 Advantages of Nano-Engineered Drug Delivery Systems

2.2.1 Ability to Cross Blood-Brain Barrier and Other Critical Systems

2.2.2 Localized Delivery-Greater Dosing Efficiency of Active Agents

2.2.3 Stabilization and Solubility

2.2.4 Surface Area

2.2.5 Sustained Delivery-Enhances Time-Release Function

2.2.6 Genomic Targeting and Gene Delivery

2.3 Overview of Commercially Available Nanotech Products in Drug Delivery, and Pending Applications

2.3.1 Dendrimers

2.3.2 Encapsulation Technologies, Coatings, Hermetic Sealants

2.3.3 Implantable Delivery Methods

2.3.4 Lipid Nanoparticles

2.3.5 External Targeting and Activation Methods for Nanoparticles: Magnetic, Ultrasound, and Radio Frequency

2.3.6 Nanotubes and Fullerenes

2.3.7 Nasal Delivery Methods

2.3.8 Pulmonary Delivery Methods

2.3.9 Quantum Dots

2.3.10 Sensors and Biomarkers

2.3.11 Cancer Therapeutics

2.3.12 Transdermal Systems

Chapter Three: The Commercialization Process -Factors in Taking a Nano-Enabled Drug Delivery System to Market

3.1 Introduction and Business Climate

3.2 Nanotechs Place in the Pharmaceutical Value Chain

3.3 Venture Capital Environment

3.4 Extension of Patent and or Product Life

3.5 Intellectual Property Overlap and Potential Litigation

3.6 The Environment for Mergers and Acquisitions

Chapter Four: Geographic Considerations for Nano-Enabled Drug Delivery Systems

4.1 United States

4.1.1 Brief Summary of Value Chain

4.1.2 Distributors / Wholesale

4.1.3 Retail

4.1.4 Patenting and Regulatory Concerns

4.2 Canada

4.2.1 Brief Summary of Value Chain and Nanotech Initiatives

4.2.2 Patenting and Regulatory Concerns

4.3 Europe

4.3.1 Brief Summary of Value Chain and Nanotech Initiatives

4.3.2 Distributors / Wholesale

4.3.3 Patenting and Regulatory Concerns

4.4 Japan

4.4.1 Brief Summary of Value Chain and Nanotech Initiatives

4.4.2 Patenting and Regulatory Concerns

4.5 Israel

4.5.1 Summary of Value Chain

4.5.2 Patenting and Regulatory Concerns

4.6 Other Countries

4.6.1 Summary

4.6.2 Patenting and Regulatory Concerns

4.6.3 The China Factor

4.6.4 The India Factor

Chapter Five: Eight-Year Market Forecasts

5.1 Forecasting Methodology

5.2 Overall Findings and Timeline for Development

5.2.1 Overall Drug Delivery Market

5.2.2 Nanotechnology-Enabled Drug Delivery Market

5.3 Forecasts by Application Type

5.3.1 Biomarker and Imaging Agents

5.3.2 Cancer Therapeutics

5.3.3 Dendrimers

5.3.4 Gene and Vaccine Delivery

5.3.5 Implantable Methods

5.3.6 Injectable and Needle-Free

5.3.7 Lipid Nanoparticles

5.3.8 Magnetic, Ultrasound, and other External Targeting Methods

5.3.9 Nanotubes and Fullerenes

5.3.10 Nasal Delivery Methods

5.3.11 Oral Delivery Methods

5.3.12 Polymeric Delivery Methods

5.3.13 Pulmonary Delivery Methods

5.3.14 Topical Delivery Systems

5.3.15 Transdermal Systems

Appendix A: List of Acronyms and Abbreviations Used in This Report

Appendix B: Contact Information for Key Firms in Nano-Enabled Drug Delivery

About the Author

List of Exhibits

• Exhibit 2-1 2002 U.S. Pharmaceutical Industry R&D Expenditures, by Phase
• Exhibit 2-2 Searchable Databases of Prior Art
• Exhibit 2-3 Schematic of Cyclosert Camptothecin
• Exhibit 2-4 Animal Treatment Response for Cyclosert Camptothecin
• Exhibit 2-5 Selected Genetic Means of Inhibiting Disease Progression
• Exhibit 2-6 Structure of Dendritic Drug Delivery Vehicles
• Exhibit 2-7 Structure of a Quantum Dot Nanocrystal
• Exhibit 2-8 Mechanism of Kereos Corps PFC Ligand Delivery Technology
• Exhibit 3-1 Projected Allocation of Funds for the 21st Century Nanotechnology R&D Act
• Exhibit 3-2 Probability of Success for a New Drug Candidate
• Exhibit 3-3 Typical Pre-IPO Investment Cycle for Start-up Companies
• Exhibit 3-4 Corporate Venture Capital Investment Activity (1994-2004)
• Exhibit 3-5 List of Pharmaceutical Corp. Venture Capital (CVC) Funds
• Exhibit 3-6 Expected Patent Life for Rx Drugs vs. Other Products
• Exhibit 3-7 Shrinking Period of Market Exclusivity Between Introduction of Breakthrough Medicine and Competing Innovators
• Exhibit 3-8 Common Methods for Resolving a Patent Dispute
• Exhibit 4-1 Typical FDA Approval Process in the Pharmaceutical Industry
• Exhibit 4-2 Desired Customer Specifications for Pharmaceutical Industry Security Inks
• Exhibit 5-1 Worldwide Market for Drug Delivery Products and Services Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-2 Worldwide Market for Nano-Enabled Drug Delivery Products and Services Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-3 Nanotechnology-Enabled Drug Deliverys Share of Overall Worldwide Market for Drug Delivery Products and Services
• Exhibit 5-4 Worldwide Market for Nano-Enabled Biomarkers and Imaging Agents Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-5 Worldwide Market for Nano-Enabled Cancer Therapeutics Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-6 Worldwide Market for Dendrimer-Based Drug Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-7 Worldwide Market for Nano-Enabled Gene & Vaccine Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-8 Worldwide Market for Nano-Enabled Implantable Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-9 Worldwide Market for Nano-Enabled Injectable & Needle-Free Delivery Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-10 Worldwide Market for Nano-Enabled Lipid Delivery Systems Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-11 Worldwide Market for Nano-Enabled Magnetic, Ultrasound, and other External Targeting Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-12 Worldwide Market for Nanotubes & Fullerenes in Drug Delivery Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-13 Worldwide Market for Nano-Enabled Nasal Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-14 Worldwide Market for Nano-Enabled Oral Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-15 Worldwide Market for Nano-Enabled Polymeric Drug Delivery Methods Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-16 Worldwide Market for Nano-Enabled Pulmonary Delivery Systems Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-17 Worldwide Market for Nano-Enabled Topical Delivery Systems Revenue Forecast ($ Million USD) and Projected Growth Rates
• Exhibit 5-18 Worldwide Market for Nano-Enabled Transdermal Delivery Systems Revenue Forecast ($ Million USD) and Projected Growth Rates